Background: Complications of chronic kidney disease (CKD) include weak bones and increased fracture risk.
Purpose: To review the benefits and harms of osteoporosis medications (bisphosphonates, teriparatide, raloxifene, and denosumab) compared with placebo, usual care, or active control in terms of bone mineral density (BMD), fractures, and safety in patients with CKD.
Data Sources: PubMed and the Cochrane Central Register of Controlled Trials from December 2006 through December 2016.
Study Selection: Paired reviewers independently screened abstracts and full-text articles for English-language, randomized, controlled trials that had at least 6 months of follow-up; evaluated osteoporosis medications among patients with CKD; and reported on BMD, fractures, or safety (mortality and adverse events).
Data Extraction: Two reviewers serially abstracted data and independently assessed risk of bias and graded the strength of evidence (SOE).
Data Synthesis: There were 13 trials (n = 9850) that included kidney transplant recipients (6 trials), patients who had stage 3 to 5 CKD or were receiving dialysis (3 trials), or postmenopausal women with CKD (4 trials). Evidence showed that bisphosphonates may slow loss of BMD among transplant recipients (moderate SOE), but their effects on fractures and safety in transplant recipients and others with CKD are unclear. Raloxifene may prevent vertebral fractures but may not improve BMD (low SOE). Effects of teriparatide and denosumab on BMD and fractures are unclear (very low SOE), and these medications may increase risk for some safety outcomes.
Limitation: Unclear rigor of evidence, possible reporting biases, and scant evidence among patients with stage 3 to 5 CKD.
Conclusion: Effects of osteoporosis medications on BMD, fracture risk, and safety among patients with CKD are not clearly established.
Primary Funding Source: Kidney Disease: Improving Global Outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/M16-2752 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The association between dietary omega-3 intake and osteoporosis: a NHANES cross-sectional study.
Front Nutr
January 2025
The Third Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: Recent research suggests that omega-3 fatty acids may play a role in bone metabolism through their influence on bone mineral density (BMD) and the regulation of bone turnover markers. However, epidemiological evidence linking omega-3 intake to the risk of developing osteoporosis is still emerging and remains inconclusive. This study aims to clarify the role of dietary omega-3 fatty acids in the prevention of osteoporosis.
View Article and Find Full Text PDFThe Association Between Tuberculosis and Osteoporosis: A Systematic Review and Meta-Analysis.
Cureus
December 2024
Internal Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THA.
Recent research suggests that tuberculosis (TB) may pose a potential risk factor for osteoporosis, although the available evidence remains limited. This study aimed to comprehensively assess osteoporosis risk in TB patients through systematic review and meta-analysis methodology. Two investigators independently conducted a literature search using the Medical Literature Analysis and Retrieval System Online (MEDLINE) and Excerpta Medica Database (EMBASE) databases up to April 2024.
View Article and Find Full Text PDFAssociation Between Allometric Body Shape Indices and Osteoporosis in Postmenopausal Women: A Cross-Sectional Study from NHANES.
Int J Womens Health
January 2025
Department of Endocrinology, The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang, People's Republic of China.
Background: Osteoporosis is a common health concern in postmenopausal women. Obesity, commonly assessed using body mass index (BMI), may have a protective effect on osteoporosis in postmenopausal women. As BMI is limited to the distinguishing fat accumulation, the study aimed to explore the association between allometric body shape indices [including a body shape index (ABSI), hip index, (HI), and waist-hip index (WHI)] and osteoporosis in postmenopausal women.
View Article and Find Full Text PDFmiR-208a-3p discriminates osteoporosis, predicts fracture, and regulates osteoclast activation through targeting STC1.
J Orthop Surg Res
January 2025
Department of Rehabilitation, The Affiliated Hospital of Youjiang Medical University for Nationalities, No.18, Zhongshan 2nd Road, Baise, 533000, Guangxi Zhuang Autonomous Region, China.
Background: Osteoporosis (OP) frequently occurs in post-menopausal women, increasing the risk of fracture. Early screening OP could improve the prevention of fractures.This study focused on the significance of miR-208a-3p in diagnosing OP and development regulation, aiming to explore a novel biomarker and therapeutic target for OP.
View Article and Find Full Text PDFSkeletal progenitor LRP1 deficiency causes severe and persistent skeletal defects with Wnt pathway dysregulation.
Bone Res
January 2025
Institute of Life Course and Medical Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor whose dysfunction is linked to developmental dysplasia of the hip, osteoporosis and osteoarthritis. Our work addresses the critical question of how these skeletal pathologies emerge. Here, we show the abundant expression of LRP1 in skeletal progenitor cells at mouse embryonic stage E10.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!